News

Orphan-drug designation for resveratrol in Melas (Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) syndrome provides company with seven years of marketing exclusivity upon receipt of FDA approval.

Under the agreement, PharmAthene has acquired all of the assets related exclusively to Avecia’s vaccines business, including the intellectual property rights associated with its recombinant Protective Antigen (rPA)

The objective of the dose-escalation trial is to determine the maximum tolerated dose of MKC-1 administered orally twice a day continuously in advanced or refractory solid tumor patients.

The trial is a randomized, open-label, prospective, multicenter study that will compare the safety and efficacy of three different Coroxane dosing schedules to primary percutaneous balloon angioplasty with

Panflu is claimed to be the first and only approved vaccine available in China against the H5N1 influenza virus. The vaccine is approved for production solely to be

The orphan drug designation encompasses all subsets of multiple myeloma and Waldenstrom’s macroglobulinemia. The orphan drug act provides the drug developer with several financial benefits and incentives related

The agreement provides for the two companies to collaborate on the development of certain orthopaedic soft tissue repair applications for which Tornier will distribute the product to its

This announcement is made following an agreement between Joe Thomas, managing member of Inpulse Phoenix and VitalCare, for 100% of Inpulse Phoenix’s interest in the Scottsdale, Arizona diabetes

The objectives of this study are to evaluate the safety of multiple doses of EVP-6124 in this patient population, to investigate potential drug-drug interactions, and to determine the